论文部分内容阅读
目的:探究分析匹多莫德结合抗传染药物医治小儿呼吸系统反复感染的临床观察。方法:依照分层抽样的方式,选取本院病例100名,病例年龄段为8至16岁儿童,不限性别,分为对照组(50例)和观察组(50例),两组分别进行不同的治疗手段,经过一年后分析两组实验儿童的治疗效果、停药后感染次数及感染持续时间等因素,整理后制作对比图表资料。结果:经过一段时间的治疗,观察组患儿的感染持续时间相对比对照组患儿对照组较短,差异显著(P<0.05),观察组患儿在停药后的传染次数相对对照组患儿变得较少,差异显著(P<0.05),观察组患儿在停药后的治疗效果相对对照组患儿更好,观察组患儿医治的总有效率为95.65%,对照组患儿治疗的总有效率为76.03%。具有统计学意义。两组患儿无不良反应发生。结论:小儿呼吸系统反复感染使用匹多莫德药物治疗可以取得较好的治疗效果:病情有明显的起色,治疗过程无不良反应,患儿反复感染次数明显减少,病情持续时间更短。因此,匹多莫德的良好治疗效果值得在临床上推广运用。
Objective: To investigate the clinical observation of pidotimod in combination with anti-infectives to treat recurrent respiratory infections in children. Methods: According to the method of stratified sampling, 100 cases of our hospital were selected. The age range of patients was 8 to 16 years old. There were no sex, divided into control group (50 cases) and observation group (50 cases) Different treatment methods, after a year of analysis of two groups of experimental children’s treatment effect, the number of infections after stopping the infection and the duration of infection and other factors, finishing the production of contrast chart data. Results: After a period of treatment, the duration of infection in the observation group was shorter than that in the control group (P <0.05). The frequency of infection in the observation group after stopping treatment was significantly higher than that in the control group Children less, the difference was significant (P <0.05), the observation group of children in the treatment of children after treatment is better than the control group, the observation group, the total effective rate of treatment was 95.65%, children in the control group The total effective rate of treatment was 76.03%. has statistical significane. Two groups of children without adverse reactions occurred. Conclusion: Repeated infection of respiratory system in children with pidotimod drug treatment can achieve better therapeutic effect: the condition has obvious improvement, no adverse reactions in the course of treatment, the number of recurrent infections in children was significantly reduced, the duration of the disease is shorter. Therefore, the good effect of pidotimod treatment worth promoting in clinical use.